The use of selegiline in Alzheimer's patients with behavior problems.

摘要: BACKGROUND Currently there is no regimen for managing the inappropriate behavior seen in Alzheimer's disease that does not cause significant patient sedation. Preliminary evidence suggests selegiline may be effective behavioral modification without adverse effects observed with other regimens. The purpose of this study was to document efficacy patients problems. METHOD Eight (6 women and 2 men) ranging age from 50 82 years (mean +/- SD = 74.0 10.5) were enrolled single-blind study. Patients received 10 mg each day 8 weeks. Prior drug administration at end Weeks 1, 2, 4, 6, 8, evaluated (BEHAVEAD), cognitive function (Mini-Mental State Examination), caregiver stress (Caregiver Burden Scale). RESULTS Of eight patients, five available analysis. No statistically differences found between mean baseline 8-week scores any three tests. However, clinical significance noted by improvement cognition (orientation recall), stress, behavior. Behavior improve areas paranoid delusional ideation, hallucinations, activity disturbances, anxiety, phobias. CONCLUSION These data suggest some problems benefit therapy.